Search research articles
Contact Us
Filters
Showing results (51-60 of 81) with videos related to
Page
of 9
Sort By:
American Journal of Cancer Research
|
July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
Tom van Meerten, John Kuruvilla, Kevin W Song, et al.
International Journal of Cancer
|
September 25, 2024
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome
Marcel Wiesweg, Claudia Küter, Johannes Schnorbach, et al.
Blood Advances
|
April 25, 2022
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
Andrew F Berdel, Leo Ruhnke, Linus Angenendt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
British Journal of Haematology
|
September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Max S Topp, Tom van Meerten, Roch Houot, et al.
Leukemia
|
June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy
Maxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
The Lancet. Oncology
|
July 15, 2019
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S Herbst, Hendrik-Tobias Arkenau, Rafael Santana-Davila, et al.
Cancer
|
March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Fredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.
Leukemia
|
April 6, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Marc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
The Lancet Regional Health. Europe
|
November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
Anika Kästner, Anna Kron, Neeltje van den Berg, et al.
Page
of 9
Search research articles
Search
Showing results (51-60 of 81) with videos related to
Sort By:
Page
of 9
American Journal of Cancer Research
|
July 15, 2024
Impact of debulking therapy on the clinical outcomes of axicabtagene ciloleucel in the treatment of relapsed or refractory large B-cell lymphoma
Tom van Meerten, John Kuruvilla, Kevin W Song, et al.
International Journal of Cancer
|
September 25, 2024
Oligometastatic non-small cell lung cancer: Impact of local and contemporary systemic treatment approaches on clinical outcome
Marcel Wiesweg, Claudia Küter, Johannes Schnorbach, et al.
Blood Advances
|
April 25, 2022
Using stroma-anchoring cytokines to augment ADCC: a phase 1 trial of F16IL2 and BI 836858 for posttransplant AML relapse
Andrew F Berdel, Leo Ruhnke, Linus Angenendt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 9, 2025
Treatment Sequences in BRAF-V600-Mutated NSCLC: First-Line Targeted Therapy Versus First-Line (Chemo-) Immunotherapy
Marcel Wiesweg, Ali Alaffas, Anna Rasokat, et al.
British Journal of Haematology
|
September 30, 2021
Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B-cell lymphoma
Max S Topp, Tom van Meerten, Roch Houot, et al.
Leukemia
|
June 21, 2020
A proof of concept phase I/II pilot trial of LSD1 inhibition by tranylcypromine combined with ATRA in refractory/relapsed AML patients not eligible for intensive therapy
Maxi Wass, Stefanie Göllner, Birgit Besenbeck, et al.
The Lancet. Oncology
|
July 15, 2019
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial
Roy S Herbst, Hendrik-Tobias Arkenau, Rafael Santana-Davila, et al.
Cancer
|
March 25, 2026
Final clinical data of a phase 1 dose-escalation study of WVT078, a BCMA×CD3 bispecific antibody, alone and in combination with γ-secretase inhibitor WHG626 in patients with relapsed and/or refractory multiple myeloma
Fredrik Schjesvold, Andrew Spencer, Yael C Cohen, et al.
Leukemia
|
April 6, 2023
Preclinical discovery and initial clinical data of WVT078, a BCMA × CD3 bispecific antibody
Marc S Raab, Yael C Cohen, Fredrik Schjesvold, et al.
The Lancet Regional Health. Europe
|
November 30, 2023
Evaluation of the effectiveness of a nationwide precision medicine program for patients with advanced non-small cell lung cancer in Germany: a historical cohort analysis
Anika Kästner, Anna Kron, Neeltje van den Berg, et al.
Page
of 9